11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 22.11.2026 Expectation: 145 pips
Invest in S&P 500 with 7,845 in mind
Yesterday at 09:49 AM 12
Period: 22.11.2026 Expectation: 2400 pips
Sell Bitcoin down to $80,500
Yesterday at 08:24 AM 12
Period: 04.11.2026 Expectation: 2700 pips
Go long on NVIDIA stock with $243 in view
21 October 2026 28
Period: 04.11.2026 Expectation: 1300 pips
EURUSD sell-off targets 1.0000
21 October 2026 29
Period: 01.11.2026 Expectation: 6300 pips
Buy Tesla stock with $430 in sight
20 October 2026 35
Period: 20.11.2026 Expectation: 1200 pips
Invest in AUDUSD ahead of Fed and RBA meetings
20 October 2026 32
Go to forecasts